Dr. Y. Nalini

Education Qualifications

• 2007: Professional Fellowship-Advanced Training in Image Guided Radio Therapy (IGRT) and Intensity Modulated Radio Therapy (IMRT) at MD Anderson Cancer Hospital, Houston, USA
• 2000: Professional Fellowship-UICC (International Union Against Cancer) ICRETT Fellowship on ‘Quality Assurance in HDR Brachytherapy’ at The Royal Marsden Hospital, London
• 1994: DNB (Radiotherapy), National Board of Examinations
• 1994: MD (Radiotherapy), Osmania Medical College, Hyderabad
• 1983: MBBS, Gandhi Medical College (Osmania University), Hyderabad

Experience

• 2009-Present: Senior Consultant Radiation Oncologist, Yashoda Hospitals, Somajiguda
• Professor, HOD & Examiner, DNB (Radiation Oncology), Yashoda Hospitals
• Dec 2004-Dec 2008: Professor, Department of Radiotherapy, MNJ Institute of Oncology (RCC), Affiliated to Osmania Medical College, Hyderabad (Postgraduate and Undergraduate Courses)
• Sep 2003-Dec 2004: Professor, Department of Radiotherapy, Government Medical College, Anantapur
• June 2001-Sep 2003: Associate Professor, Rangaraya Medical College, Kakinada
• 1995: Consultant Radiation Oncologist, Apollo Cancer Hospital, Hyderabad
• 1994-2001: Assistant Professor, Department of Radiotherapy, Osmania Medical College

Services offered

• External Beam Radiotherapy with 3DCRT, IMRT, VMAT (RapidArc)
• Advanced Techniques-Stereotactic Radio Surgery (SRS)
• Advanced Techniques-Stereotactic Body Radio Therapy (SBRT)
• Advanced Techniques-Image Guided Radio Therapy (IGRT)
• Radiotherapy for Breast Cancer-Hypofractionation (less number of sittings for radiation) and DIBH Technique in Left Sided Breast Cancers, Breast Conservation Therapy
• Radiation Therapy for Gynecological Cancers-IMRT, RapidArc, IGRT, Brachytherapy
• Head and Neck Cancers-Concurrent/Simultaneous Chemoradiotherapy, IMRT, IGRT & VMAT
• Liver and Lung Cancers
• Sarcomas and Brain Tumor
• Pediatric Cancers
• Brachytherapy-Intracavitary Radiation (ICR), Image Guided Brachytherapy & Intraluminal Radiotherapy (ILRT)
• Palliative Radiotherapy and Supportive Treatment
• Preventive Cancer Screening-Pap Smear, Mammogram, etc

Special Interest and Expertise

• Expertise in the Management of Solid Tumors with Simultaneous Chemotherapy, Targeted Therapy and Hormonal Therapy
• Gastrointestinal Cancers and Breast Cancers with Specialization in Internal Modulated Radiotherapy
• Image-Guided Radiotherapy and RapidArc Radiotherapy & Stereotactic Body Radiation Therapy

Professional Membership

• Association of Radiation Oncologists of India (AROI)
• American Society for Therapeutic Radiology and Oncology (ASTRO)
• Indian Medical Association (IMA)
• Union for International Cancer Congress (UICC)

Research & Publications

• Co-investigator in Multicenteric five arm study for efficacy and toxicity of ‘Wobe Mugose E’ in reducing radiation toxicity
• Co-investigator in ATLAS Study: International ATLAS (Adjuvant Tamoxifen Longer Against Shorter) Breast Cancer Treatment Trial
• Open, Uncontrolled, Multicentre, Phase II Asia/Australian Study of Erbitus'R' (Cetuximab) in combination with Irinotecan in patients with Metastatic Colorectal Adenocarcinoma expressing the Epidermal Growth Factor Receptor (EGFR) and having progressed on defined Irinotecan-based regimen as most recent treatment
• Trial Investigator in ToGA Study (NCT01041404)-A Study of Herceptin (Trastuzumab) in Combination with Chemotherapy Compared with Chemotherapy Alone in Patients with HER2-Positive Advanced Gastric Cancer
• An Open Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced Metastatic Breast Cancer
• A Randomized, Open Label, Multicentre Study of VELCADE with Rituximab or Rituximab alone in subjects with relapsed or refractory, rituximab naive or sensitive follicular B-cell Non-Hodgkin's Lymphoma. Protocol 26866138-LYM-3001; Phase 3
• A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel in Combination with ZD6474 (ZACTIMA ) versus Docetaxel in combination with placebo in patients with locally advanced or metastatic (Stage IIIb-IV) Non-Small Cell Lung Cancer after Failure of 1st Line Anti-Cancer Therapy
• Multiple Myeloma-A Phase I/II a, Open-Label, Dose-Escalation Study to Determine the Safety and Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients with Advanced Multiple Myeloma
• Phase III Study of Lucanix tm (Belagenpumatucel - L) in Advanced Non-Small Cell Lung Cancer: An International Multicenter, Randomized, Double-Blinded, Placebo controlled Study of Lucanix tm Maintenance Therapy for Stages III/IV NSCLC Subjects Who have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy
• Oral Presentation 'Tropical Cephalalgia-a new clinical entity of headache' at 54 th Annual Scientific Meeting of American Headache Society, June 2012 at Los Angeles, USA
• Poster Presentation in XVI (UICC) International Cancer Congress held in 1994 at New Delhi titled `Concomitant Chemotherapy with cisplatin and 5 FU in advanced carcinoma, of oral cavity and oropharynx’.
• Poster Presentation “Analysis of patients attending the headache clinic-An Indian Experience” at 'World Headache 2000' at London in the year 2000. Abstract published in the Journal Cephalalgia 2000; 20:307
• Yadala Nalini, Vivek Yadala, Sunil Devika, Swamy S Thirumalai. Rapid arc radiotherapy in a patient with bilateral breast carcinoma-10 year follow up. International Journal of contemporary medical research. Research ISSN (Online): 2393-915X; (Print): 2454-7379 | ICV: 98.46 | Volume 6 | Issue 12 | December 2019
• 'A retrospective study of thousand pap smears at Tertiary Care Centre.' International Journal of contemporary medical research. Research ISSN (Online): 2393-915X; (Print): 2454-7379 | ICV: 77.83 | Volume 4 | Issue 12 | December 2017
• A rare case of fever of unknown origin: subcutaneous panniculitis like T-cell lymphoma' BMJ case reports 2015.doi:10-1136 / bcr-2015-211355
• 'Multiple aneurysms and Rosai-Dorfman`s disease-Association or coincidence?' BMJ case reports 2015;doi:10.1136/bcr-2015-212189
• 'Huge mediastinal mass with minimal symptoms: thymolipoma.' BMJ case reports 2011;doi:10.1136/bcr.02.2010.8984
• 'Analysis of patients attending headache clinic: Indian experience'. Cephaialgia May 2000,20(4) 307
• 'Parasites and headache-Indian experience.' Headache: The Journal of Head and Face Pain, June 2002
• 'Headache Scenario-South India' (Tropical Cephalalgia) Headache: The Journal of Head and Face Pain, Vol 42 Issue(5) (2002)

FAQ'S

1. 1. Why do patients frequently visit Dr. Y. Nalini?
   

   Patients frequently visit Dr. Y. Nalini for radiotherapy for breast cancer, radiation therapy for gynecological cancers, head and neck cancers, liver and lung cancers, sarcomas and brain tumor, pediatric cancers.

2. 2. What is Dr. Y. Nalini's education qualification?
   

   Dr. Y. Nalini has the following qualifications – MBBS, MD (Radiotherapy), DNB (Radiotherapy).

3. 3. What does Dr. Y. Nalini specializes in?
   

   Dr. Y. Nalini is specialized in the management of solid tumors with simultaneous chemotherapy, targeted therapy and hormonal therapy, treatment of gastrointestinal cancers and breast cancers with specialization in Internal Modulated Radiotherapy, Image-Guided Radiotherapy and RapidArc Radiotherapy & Stereotactic Body Radiation Therapy.

4. 4. Where does Dr. Y. Nalini practice?
   

   Dr. Y. Nalini practices at Yashoda Hospitals – Somajiguda.

5. 5. How can I book Dr. Y. Nalini appointment?
   

   You can book Dr. Y. Nalini’s appointment online for Online video consultation and Opd consultation.

6. 6. How many years of experience does Dr. Y. Nalini have?
   

   Dr. Y. Nalini has 28 years of experience as a Radiation Oncologist.